The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy

Metabolism: Clinical and Experimental

Volumn 55, Issue 12, 2006, Pages 1645-1652

  Matsumoto, Sachiko ^a   Takebayashi, Kohzo ^a   Aso, Yoshimasa ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; CREATININE; HEMOGLOBIN A1C; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; VISFATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ADIPONECTIN; AGED; BODY MASS INDEX; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548513414     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.07.025     Document Type: Article

References (35)

1. Kumada M., Kihara S., Sumitsuji S., et al. Coronary artery disease. Association of hypoadeponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
2. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
3. Shimomura I., Funahashi T., Takahashi M., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2 (1996) 800-803
4. Togashi N., Ura N., Higashiura K., et al. The contribution of skeletal muscular tumor necrosis factor α to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18 (2000) 1-6
5. Meigs J.B., Mittleman M.A., Nathan D.M., et al. Hyperinsulinemia, hyperglycemia and impaired hemostasis. The Framingham Offspring study. JAMA 283 (2000) 221-228
6. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (2002) 57-58
7. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
8. Shimada K., Miyazaki T., and Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta 344 (2004) 1-12
9. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science (2005) 426-430
10. Dzau V.J. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
11. Adamczak M., Zeier M., Dikow R., et al. Kidney and hypertension. Kidney Int 80 (2002) 62-67
12. Folli F., Kahn C.R., Hansen H., et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100 (1997) 2158-2169
13. Engeli S., Schling P., Gorzelniak K., et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003) 807-825
14. Furuhashi M., Ura N., Higashiura K., et al. Blockade of the renin-angiotensin system increase adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
15. Nomura S., Shouzu A., Omoto S., et al. Effect of valsartan on monocyte/endothelial activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 117 (2006) 385-392
16. Virdis A., Neves M.F., Amiri F., et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
17. Rocha R., Stier Jr. C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 (2000) 3871-3878
18. Pascual-Le Tallec L., and Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 19 (2005) 2211-2221
19. Rossing K., Schjoedt K.J., Smidt U.M., et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double masked, cross-over study. Diabetes Care 28 (2005) 2106-2112
20. Rachmani R., Slavachevsky I., Amit M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21 (2004) 471-475
21. Jawa A., Nachimuthu S., Pendergrass M., et al. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin converting enzyme inhibitor therapy. J Clin Endocrinol Metab 91 (2006) 31-35
22. Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
23. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD 40 ligand in acute coronary syndrome. N Engl J Med 348 (2003) 1104-1111
24. American Diabetes Association. Diabetic nephropathy. Diabetes Care 22 (1999) S66
25. Davis M.D. Natural evolution. In: L'Esperance Jr. F.A. (Ed). Current diagnosis and management of chorioretinal disease (1974), Mosby, St Louis (Mo) 179-184
26. Diabetes Treatment Guideline 2004-2005 edited by Japan Diabetes Society. Tokyo, Japan, Bunkodo (in Japanese).
27. Wakabayashi S., and Aso Y. Adiponectin concentration in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart variation. Diabetes Care 27 (2004) 2392-2397
28. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
29. Brown N.J., Nakamura S., Ma L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 9 (2000) 1219-1227
30. Yalcin A.U., Dincer M., Aslan V., et al. Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 25 (2002) 260-264
31. Walmsely D., Hampton K.K., and Grant P.J. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabet Med 8 (1991) 954-959
32. Festa A., D'Agostino Jr., Tracy R.P., et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The insulin resistance atherosclerosis study. Diabetes (2002) 1131-1137
33. Tsutamoto T., Maeda K., Mabuchi N., et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 36 (2000) 838-844
34. Feola M., Menardi E., Ribichini F., et al. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. Med Sci Monit 9 (2003) 341-345
35. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717